ProCE Banner Activity

Novel Therapies, Improving Adherence, and Reducing Disparities in Psoriasis Care

Clinical Thought

This expert commentary reviews strategies for incorporating new and emerging therapies, improving medication adherence, and addressing healthcare disparities for patients with moderate to severe psoriasis.


In Collaboration With Clinical Care Options, LLC

Released: September 16, 2022

Expiration: September 15, 2023

Begin Activity

Share

Faculty

Steven Feldman

Steven Feldman, MD, PhD

Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Acknowledgement

This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Sanofi and Regeneron Pharmaceuticals.

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation.

Target Audience

Dermatologists and APPs and nurses who practice in dermatology.

Disclosure

Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun Pharma, Union Chimique Belge (UCB), vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.

Format

ClinicalThought

Additional Information

Program Medium

This program has been made available online.